News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Prima Biomed (PRR.AX) Shareholders' Briefing Webcast & Dial In Details



6/13/2012 8:45:14 AM

SYDNEY, AUSTRALIA--(Marketwire - June 12, 2012) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) confirms the webcast and dial in details for the shareholder briefing to be held on Friday 15th June 2012, at 9:30am (Sydney time).

Webcast link

Shareholders who are unable to attend the meeting and wish to view the proceedings on the Webcast should use the following link:

http://events.knowledgevision.com/staging/The_Prima_Biomed_Shareholder_Briefing.html

Shareholders who would also like to ask a question at the meeting are requested to dial in on one of the following numbers:

Dial in Numbers:

Australia Toll Free                1 800 131 617       
Australia Alternate Toll Free      1 800 838 758       
Canada/USA                         1 855 624 0077      
China Wide                         10 800 140 1776     
France                             0800 913 734        
Germany                            0800 183 0918       
Hong Kong                          0800 968 273        
India                              0008 0010 08070     
Indonesia                          001 803 321 8057    
Ireland                            1800 948 607        
Japan                              006633 868000       
Malaysia                           1800 816 441        
New Zealand                        0800 452 795        
Singapore                          800 101 2702        
South Africa                       0800 984 013        
Switzerland                        0800 802 498        
Taiwan                             0080 112 7377       
UAE                                8000 3570 2706      
United Kingdom                     0800 051 1453       

About Prima BioMed

Prima BioMed is a global biotechnology company headquartered in Australia. As a leader in personalized bio-therapeutic products for cancer, Prima is dedicated to leveraging its current technology and expertise to develop innovative treatment options for patients and maximize value to shareholders. Prima's lead product is CVac™, an autologous dendritic cell product currently in clinical trials for ovarian cancer.


For further information please contact:

Mr James Moses
Investor and Media Relations
Mandate Corporate
Ph: +61 (0) 420 991 574
E: Email Contact


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES